You are here: Home » News-CM » Companies » News
Business Standard

Sun Pharma launches CEQUA 0.09% in US

Capital Market 

Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries has commercialized CEQUA (cyclosporine ophthalmic solution) 0.09% in the U. S. CEQUA, which offers the highest concentration of cyclosporine for ophthalmic use approved by the U.

S. Food and Drug Administration (FDA), is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye), an inflammatory disease that afflicts more than 16 million people in the U. S.1 CEQUA is the first and only FDA-approved cyclosporine treatment delivered with nanomicellar (NCELL) technology, which helps to improve the bioavailability and physicochemical stability of cyclosporine, resulting in improved ocular tissue penetration.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, October 14 2019. 09:28 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU